aTyr Pharma, Inc., Annual General Meeting, May 11, 2026 Mar 14
aTyr Pharma, Inc. Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis Feb 03
Atyr Pharma Receives Deficiency Notice for Non-Compliance with Nasdaq Listing Rules Dec 06
A New aTyr Pharma, Inc. Securities Class Filed; Class Period Significantly Enlarged Nov 12
Shamis & Gentile, P.A. Files Securities Class Action Lawsuit Against aTyr Pharma, Inc Oct 11
aTyr Pharma, Inc. Presents Additional Findings from Phase 3 EFZO-FIT™? Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 Sep 30
Atyr Pharma Announces Topline Results from Phase 3 Efzo-Fit™? Study of Efzofitimod in Pulmonary Sarcoidosis Sep 15
aTyr Pharma, Inc. Announces Last Patient Visit in Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis Jul 22
aTyr Pharma, Inc. Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-Connect™? Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) Jun 04
aTyr Pharma, Inc Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis May 15
aTyr Pharma, Inc. Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise Mar 26
aTyr Pharma, Inc., Annual General Meeting, May 01, 2025 Mar 21
aTyr Pharma, Inc. Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™? Study in Pulmonary Sarcoidosis Mar 07
aTyr Pharma, Inc. to Report Q4, 2024 Results on Mar 13, 2025 Mar 04
aTyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors Dec 13
aTyr Pharma, Inc. Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis Dec 10
New minor risk - Profitability Nov 08
Independent Director recently bought €170k worth of stock Jul 25
aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis Jul 22
Independent Chairman of the Board recently bought €81k worth of stock Jun 05
aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis May 15
aTyr Pharma, Inc., Annual General Meeting, May 22, 2024 Apr 06
New major risk - Share price stability Mar 15
New major risk - Revenue size Mar 15
Forecast to breakeven in 2026 Mar 15
aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024 Feb 29
aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis Feb 21
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild Nov 01
Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes Sep 12
Independent Director recently bought €410k worth of stock May 12
Insufficient new directors Nov 16
aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest Nov 10
aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis Sep 28
aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis Aug 13
aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 05
Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod May 18
aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
Insufficient new directors Apr 27
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference Apr 03
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 16
aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name Jan 14
Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020) Nov 11
aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis Sep 14
Independent Director recently bought €163k worth of stock May 22
Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019) Mar 25
aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021 Mar 17
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications Mar 16
Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor Mar 12
aTyr Pharma Announces New tRNA Synthetase Discovery Programs Feb 13
New 90-day high: €6.35 Feb 10
aTyr Pharma, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Jan 05
aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis Dec 23
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline Nov 11
aTyr Pharma, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 06
aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Oct 27
aTyr Pharma, Inc. announced that it expects to receive $20 million in funding from Aspire Capital Partners, LLC Sep 18
aTyr Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020 Aug 07 
